Thyroid  	Thyroid  	 JJ	B-NP
cysts  	cysts  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
sclerosing  	sclerosing  	 JJ	B-NP
agent  	agent  	 NN	I-NP
Atossiclerol 	Atossiclerol 	 NNP	I-NP
.  	.  	 .	O
Long-term  	Long-term  	 JJ	O
( 	( 	 -LRB-	O
5  	5  	 CD	O
to  	to  	 TO	O
15  	15  	 CD	O
years 	years 	 NNS	O
)  	)  	 -RRB-	O
follow-up  	follow-up  	 :	O
The  	The  	 DT	O
aim  	aim  	 NN	O
of  	of  	 IN	O
this  	this  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
long-term  	long-term  	 JJ	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
sclerosing  	sclerosing  	 JJ	B-NP
agent  	agent  	 NN	I-NP
Atossisclerol  	Atossisclerol  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
benign 	benign 	 JJ	O
,  	,  	 ,	O
ecolucent 	ecolucent 	 NN	B-NP
,  	,  	 ,	O
thyroid  	thyroid  	 JJ	O
cysts 	cysts 	 NN	O
.  	.  	 .	O
Two  	Two  	 CD	O
groups  	groups  	 NNS	O
of  	of  	 IN	O
cysts 	cysts 	 NN	O
,  	,  	 ,	O
one  	one  	 CD	O
between  	between  	 IN	O
1  	1  	 CD	O
and  	and  	 CC	O
3  	3  	 CD	O
cm  	cm  	 NNS	O
and  	and  	 CC	O
a  	a  	 DT	O
group  	group  	 NN	O
smaller  	smaller  	 JJR	O
than  	than  	 IN	O
0.99  	0.99  	 CD	O
mm  	mm  	 NN	O
in  	in  	 IN	O
maximum  	maximum  	 JJ	O
diameter  	diameter  	 NNS	O
( 	( 	 -LRB-	O
range  	range  	 NN	O
0.6-0.99 	0.6-0.99 	 CD	O
)  	)  	 -RRB-	O
were  	were  	 VBD	O
considered  	considered  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
inclusion  	inclusion  	 NN	B-NP
plan 	plan 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
localization  	localization  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
cysts  	cysts  	 NN	O
was  	was  	 VBD	O
at  	at  	 IN	O
lobar  	lobar  	 JJ	B-NP
level 	level 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
limited  	limited  	 JJ	O
quantity  	quantity  	 NN	O
of  	of  	 IN	O
Atossisclerol  	Atossisclerol  	 NNP	B-NP
( 	( 	 -LRB-	O
0.5  	0.5  	 CD	O
to  	to  	 TO	O
2 	2 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
was  	was  	 VBD	O
injected 	injected 	 VBN	O
.  	.  	 .	O
No  	No  	 DT	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
were  	were  	 VBD	O
noted 	noted 	 VBN	O
.  	.  	 .	O
After  	After  	 IN	O
5  	5  	 CD	O
years  	years  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
group  	group  	 NN	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
sclerosing  	sclerosing  	 JJ	B-NP
agent  	agent  	 NN	I-NP
93 	93 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
cysts  	cysts  	 NN	O
were  	were  	 VBD	O
completely  	completely  	 RB	O
disappeared  	disappeared  	 VBD	O
( 	( 	 -LRB-	O
vs  	vs  	 CD	O
60 	60 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
controls 	controls 	 NNS	O
) 	) 	 -RRB-	O
.  	.  	 .	O
However  	However  	 RB	O
the  	the  	 DT	O
initial  	initial  	 JJ	O
target  	target  	 NN	B-NP
cyst  	cyst  	 NN	I-NP
at  	at  	 IN	O
5  	5  	 CD	O
and  	and  	 CC	O
years  	years  	 NNS	O
was  	was  	 VBD	O
completely  	completely  	 RB	O
cured  	cured  	 VBN	O
in  	in  	 IN	O
most  	most  	 JJS	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
> 	> 	 CD	O
80 	80 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
sclerosing  	sclerosing  	 JJ	B-NP
agent 	agent 	 NN	I-NP
;  	;  	 :	O
at  	at  	 IN	O
10  	10  	 CD	O
years  	years  	 NNS	O
more  	more  	 RBR	O
than  	than  	 IN	O
90 	90 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
original 	original 	 JJ	O
,  	,  	 ,	O
sclerosed  	sclerosed  	 JJ	B-NP
target  	target  	 NN	I-NP
cysts  	cysts  	 NNS	I-NP
were  	were  	 VBD	O
not  	not  	 RB	O
visible 	visible 	 JJ	O
.  	.  	 .	O
Another  	Another  	 DT	O
control  	control  	 NN	O
of  	of  	 IN	O
most  	most  	 JJS	O
of  	of  	 IN	O
these  	these  	 DT	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
53 	53 	 CD	O
/ 	/ 	 CD	O
68 	68 	 CD	O
)  	)  	 -RRB-	O
at  	at  	 IN	O
15  	15  	 CD	O
years  	years  	 NNS	O
indicated  	indicated  	 VBD	O
that  	that  	 DT	O
sclerosis  	sclerosis  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
cyst  	cyst  	 NN	O
is  	is  	 VBZ	O
safe  	safe  	 JJ	O
and  	and  	 CC	O
allow  	allow  	 VB	O
a  	a  	 DT	O
better  	better  	 RBR	O
occlusion 	occlusion 	 JJ	O
/ 	/ 	 CD	O
obliteration  	obliteration  	 NNS	O
( 	( 	 -LRB-	O
in  	in  	 IN	O
almost  	almost  	 RB	O
all  	all  	 DT	O
patients 	patients 	 NNS	O
)  	)  	 -RRB-	O
of  	of  	 IN	O
the  	the  	 DT	O
cyst  	cyst  	 NN	O
in  	in  	 IN	O
comparison  	comparison  	 NN	O
with  	with  	 IN	O
aspiration  	aspiration  	 VBG	B-NP
only  	only  	 RB	O
( 	( 	 -LRB-	O
slow  	slow  	 JJ	O
recurrence  	recurrence  	 NN	O
in  	in  	 IN	O
some  	some  	 DT	O
25 	25 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
cysts 	cysts 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
sclerosing  	sclerosing  	 JJ	B-NP
agent  	agent  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
re-injected  	re-injected  	 JJ	O
in  	in  	 IN	O
the  	the  	 DT	O
same  	same  	 JJ	O
patients  	patients  	 NNS	O
without  	without  	 IN	O
significant  	significant  	 JJ	O
reaction  	reaction  	 NN	O
or  	or  	 CC	O
clinical  	clinical  	 JJ	B-NP
problems  	problems  	 NNS	I-NP
or  	or  	 CC	O
immunological  	immunological  	 JJ	B-NP
reactions 	reactions 	 NNS	I-NP
.  	.  	 .	O
